MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1183/13993003.02024-2021

Медицинская библиотека · The European respiratory journal · 2022

Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry.

Hoeper Marius M, Pausch Christine, Grünig Ekkehard, Staehler Gerd, Huscher Doerte, Pittrow David, Olsson Karen M, Vizza Carmine Dario, Gall Henning, Distler Oliver, Opitz Christian, Gibbs J Simon R, Delcroix Marion, Ghofrani H Ardeschir, Rosenkranz Stephan, Park Da-Hee, Ewert Ralf, Kaemmerer Harald, Lange Tobias J, Kabitz Hans-Joachim, Skowasch Dirk, Skride Andris, Claussen Martin, Behr Juergen, Milger Katrin, Halank Michael, Wilkens Heinrike, Seyfarth Hans-Jürgen, Held Matthias, Dumitrescu Daniel, Tsangaris Iraklis, Vonk-Noordegraaf Anton, Ulrich Silvia, Klose Hans

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Since 2015, the European pulmonary hypertension guidelines recommend the use of combination therapy in most patients with pulmonary arterial hypertension (PAH). However, it is unclear to what extent this treatment strategy is adopted in clinical practice and if it is associated with improved long-term survival.

METHODS

We analysed data from COMPERA, a large European pulmonary hypertension registry, to assess temporal trends in the use of combination therapy and survival of patients with newly diagnosed PAH between 2010 and 2019. For survival analyses, we looked at annualised data and at cumulated data comparing the periods 2010-2014 and 2015-2019.

RESULTS

A total of 2531 patients were included. The use of early combination therapy (within 3 months after diagnosis) increased from 10.0% in patients diagnosed with PAH in 2010 to 25.0% in patients diagnosed with PAH in 2019. The proportion of patients receiving combination therapy 1 year after diagnosis increased from 27.7% to 46.3%. When comparing the 2010-2014 and 2015-2019 periods, 1-year survival estimates were similar (89.0% (95% CI 87.2-90.9%) and 90.8% (95% CI 89.3-92.4%), respectively), whereas there was a slight but nonsignificant improvement in 3-year survival estimates (67.8% (95% CI 65.0-70.8%) and 70.5% (95% CI 67.8-73.4%), respectively).

CONCLUSIONS

The use of combination therapy increased from 2010 to 2019, but most patients still received monotherapy. Survival rates at 1 year after diagnosis did not change over time. Future studies need to determine if the observed trend suggesting improved 3-year survival rates can be confirmed.

Для цитирования: Hoeper Marius M, Pausch Christine, Grünig Ekkehard, Staehler Gerd, Huscher Doerte, Pittrow David, Olsson Karen M, Vizza Carmine Dario, Gall Henning, Distler Oliver, Opitz Christian, Gibbs J Simon R, Delcroix Marion, Ghofrani H Ardeschir, Rosenkranz Stephan, Park Da-Hee, Ewert Ralf, Kaemmerer Harald, Lange Tobias J, Kabitz Hans-Joachim, Skowasch Dirk, Skride Andris, Claussen Martin, Behr Juergen, Milger Katrin, Halank Michael, Wilkens Heinrike, Seyfarth Hans-Jürgen, Held Matthias, Dumitrescu Daniel, Tsangaris Iraklis, Vonk-Noordegraaf Anton, Ulrich Silvia, Klose Hans. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry.. The European respiratory journal. 2022. DOI: 10.1183/13993003.02024-2021.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.